(Glucagon + insulin human) by Abvance Therapeutics for Hypoglycemia: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Glucagon + insulin human) overview
ABV-100 is under development for the treatment of hypoglycemia. It is a fixed dose combination of glucagon and rapidly acting insulin which acts by targeting glucagon and insulin receptors. It is administered by intravenous route.
For a complete picture of (Glucagon + insulin human)’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#Glucagon #insulin #human #Abvance #Therapeutics #Hypoglycemia #Likelihood #Approval
